Desvenlafaxine-@Serotinin & norephinephrine reuptake inhb
Drug Name:
Desvenlafaxine-@Serotinin & norephinephrine reuptake inhb
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Serotin and Norephinephrine reuptake inhibitors - include Duloxetine and Desvenlafaxine Refer - Duloxetine
As desvenlafaxine is primarily metabilosed through conjugation drugs that affect the CYP 450 isoenzymes are unlikely to have a significant effect on desvenlafaxine levels. It should be used in caution with other serotonigic agents such as antidepressants, stimulants, 5HT , agonists and opioids, as the risk of developing serotonin syndrome may be increased
Indication:
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Desvenlafaxine Succinate ER tablets 18-07-2009
50mg /100mg
For the treatment of Major depressive disorde (MDD)
Major depressive disorder
Serotin and Norephinephrine reuptake inhibitors - include Duloxetine and Desvenlafaxine Refer - Duloxetine
Adverse Reaction:
Most common adverse effects reported were nausea and dizziness. Due to its noradrenergic action,desvenlafaxine may increase blood pressure and heart rate during therapy. Other minor adverse effects that may occur include diarrhea, anxiety, sexual dysfunctiion , abnormal bleeding and hyponatemia
Contra-Indications:
Patients hypersensitive to Desvenlafaxine succinate, Venlafaxine Hydrocholride or any excepients in the formuation and patients taking monoamine Oxidase Inhibitors ( MAOIs)
Dosages/ Overdosage Etc:
For the treatment of Major depressive disorde (MDD)
Major depressive disorder
Desvenlafaxine 50mg to 100 mg extended -release tablet is recommended per day
Patient Information:
Serotin and Norephinephrine reuptake inhibitors - include Duloxetine and Desvenlafaxine
Refer - Duloxetine
Pharmacology/ Pharmacokinetics:
Pharmacodynamics
Desvenlafaxine acts by preventing thereuptaker of serotinin and norepinephrine by nerves after their release. Since uptake is an important mechansim for removing released neurotransmitters and terminating their actions on adjacent nerves, the reduced uptake caused by desvenlafaxine increases the effect of serotonin and norephinephrine in the brain.
Pharmacokinetics
Desvenlafaxine administered orally as single dose 50mg or 100mg (once-a - day) shows linear and dose proportional pharmacokinetics in a dose range between 100mg/day to 600mg/day. The mean terminal half-life is approximately 11 hours with maximum plasma concentration of 7.5hrs of oral administration. The bsolute bio-availability od desvenlafaxine oral formulation is found to be 80% and absorption minimally affected by food It undergoes minimal metabolism via the CYP 450 isoenzymes and 5% of ther dose is excreted unchanged in the urine.
Interaction with Food:
Absorption minimally affected by food
